Compare NPO & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPO | WGS |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.6B |
| IPO Year | N/A | N/A |
| Metric | NPO | WGS |
|---|---|---|
| Price | $229.40 | $104.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $243.33 | $138.13 |
| AVG Volume (30 Days) | 182.0K | ★ 491.9K |
| Earning Date | 02-18-2026 | 02-23-2026 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | ★ 58.40 | N/A |
| EPS | ★ 4.06 | 0.07 |
| Revenue | ★ $1,106,300,000.00 | $402,190,000.00 |
| Revenue This Year | $8.71 | $41.17 |
| Revenue Next Year | $9.74 | $23.53 |
| P/E Ratio | ★ $57.89 | $1,493.63 |
| Revenue Growth | 6.44 | ★ 50.50 |
| 52 Week Low | $133.50 | $55.17 |
| 52 Week High | $248.88 | $170.87 |
| Indicator | NPO | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 55.97 | 22.81 |
| Support Level | $214.10 | $124.26 |
| Resistance Level | $239.00 | $140.83 |
| Average True Range (ATR) | 6.79 | 7.45 |
| MACD | 1.52 | -2.80 |
| Stochastic Oscillator | 62.19 | 1.44 |
Enpro Inc formerly EnPro Industries Inc is a United States-based company that designs, develops, manufactures, and markets proprietary engineered industrial products. The company operates through three segments: Sealing Technologies, which derives maximum revenue, manufactures and markets sealing products, wheel-end components & systems; and Advanced Surface Technologies manufactures wafer processing sub-systems, thin-film coatings, optical filters, and other services like cleaning, coating, testing, and refurbishment. Its geographical segments are the United States, Europe, and other foreign countries.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.